Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 18 November 2025 - 24 November 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) Stock Today: ‘Hold’ Rating, New Institutional Buying and AI Drug Discovery Hype — November 23, 2025

Recursion Pharmaceuticals (RXRX) closed Friday at $4.17, up 8.31%, with volume near 33 million shares and trading near its 52-week low. MarketBeat reports a consensus “Hold” rating, with a $7.25 average price target and Q3 revenue down 80% year-on-year. Kingsview Wealth Management increased its RXRX stake by over 500% in Q2. About 89% of shares are institutionally held.
24 November 2025
···
Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals Stock on November 23, 2025: Tonmya Launch, Bigger Buyback, and a $400M ATM Shape the TNXP Trade

Tonix Pharmaceuticals’ first commercial fibromyalgia drug, Tonmya, is now available in U.S. pharmacies following FDA approval in August. TNXP shares closed Friday at $16.10, up 2.94%, but remain down about 51% for 2025. Market cap stands near $141 million, with negative net margins and a price-to-sales ratio of 13.7. Expanded share repurchase and ATM equity programs are in place.
23 November 2025
··
Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer (PFE) on 23 Nov 2025: Metsera Deal, Cancer Win and a 7% Dividend

Pfizer closed Friday at $25.04 per share, with a market cap near $140 billion and a dividend yield close to 7%. The company finalized a multibillion-dollar obesity drug acquisition, won a major U.S. cancer approval, issued $6 billion in bonds, and settled a $41.5 million lawsuit in Texas. Shares remain over 60% below pandemic highs. New analysis highlights both upside and ongoing risks.
23 November 2025
··
Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer Stock Today, November 22, 2025: 7% Dividend, $6 Billion Bond Sale and New Health Scare Put PFE Back in Focus

Pfizer closed Friday at $25.04, up 2.6%, with trading volume above 72 million shares. The company completed a $6 billion bond offering late Friday, spanning maturities from 2027 to 2065. Pfizer’s stock is down about 12% over the past year, despite a recent FDA cancer-drug approval and a multi-billion-dollar obesity drug deal. Dividend yield stands near 6.9%.
23 November 2025
···
Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer (PFE) Stock Rallies on November 21, 2025 as Investors Focus on FDA Win, Obesity Pivot and 7% Dividend Yield

Pfizer shares rose 2.62% to close at $25.04 Friday after the FDA approved PADCEV plus Keytruda for muscle-invasive bladder cancer and positive data emerged for its mRNA flu vaccine. Volume reached 73 million shares. The stock outperformed Johnson & Johnson and Eli Lilly but remains about 10% below its 52-week high. Pfizer is still down for the year and trades well below pandemic-era peaks.
22 November 2025
··
Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck (MRK) Stock Today: Mini‑Tender Warning, Dividend Hike and Drug Wins – 22 November 2025

Merck urged shareholders to reject Tutanota LLC’s unsolicited mini-tender offer of $65 per share, about 25–32% below recent prices. The company raised its quarterly dividend to $0.85 and reported FDA approval for new Keytruda-based bladder cancer treatments. Merck stock traded near $97.76 Friday, up 2.9%, with a market cap of $243 billion.
22 November 2025
···
Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk Stock on 21 November 2025: NVO Slips as Denmark Grants Eye-Damage Payouts and GLP‑1 Price War Escalates

Novo Nordisk’s U.S. shares fell 1.1% to $47.07 by late morning, while Copenhagen B-shares closed down nearly 3% at DKK 305, extending a year-to-date drop of about 45%. Denmark compensated four patients for vision loss linked to Wegovy and Ozempic. Novo Nordisk and Eli Lilly launched direct-to-employer GLP-1 drug programs, and Novo cut self-pay prices for its weight-loss drugs.
21 November 2025
···
Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer Stock Today (PFE): mRNA Flu Breakthrough, $6B Metsera Bonds and a 7% Dividend – Nov. 21, 2025

Pfizer shares closed up just over 3% at $25.18 on Friday after positive Phase 3 mRNA flu vaccine results, then fell to $24.36 in after-hours trading. The company also completed a $6 billion bond sale to help fund its $10 billion Metsera obesity-drug deal. Pfizer stock remains down about 8% for the year, trailing large-cap pharma peers.
21 November 2025
···
Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (TELO) Unveils Leukemia Breakthrough and Board Change – Full Investor Update for November 21, 2025

Telomir Pharmaceuticals (NASDAQ: TELO) reported new preclinical data showing its lead drug Telomir-1 killed HL60 leukemia cells in vitro. Director Dr. Craig Eagle resigned from the board, effective November 14, with no dispute cited. TELO stock jumped 8% pre-market but recently traded at $1.39, down 3% from the prior close. Shares remain down about two-thirds year-to-date.
21 November 2025
··
Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer Stock Today, November 20, 2025: Price Slide, Dividend Debate, Flu Shot Win and Texas Settlement

Pfizer shares fell 1.7% to about $24.45 on November 20, 2025, with over 44 million shares traded. The stock’s near-7% dividend yield drew attention, but investors weighed legal concerns, new R&D developments, and uncertainty over post-COVID growth. Pfizer’s quarterly EPS dropped 20% year-over-year to $0.62, with a dividend payout ratio near 70%. Management has not indicated plans to cut the dividend.
20 November 2025
···
Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) Jumps as It Secures Pharmaceutical‑Grade Ibogaine Supply for Global Clinical Trials – 20 November 2025

Psyence BioMed (NASDAQ: PBM) secured a sustainable supply of pharmaceutical-grade ibogaine through PsyLabs, receiving an initial 50 kg shipment of high-potency iboga bark for processing. PBM shares rose 21.5% to $3.39 in pre-market trading Thursday, after being named among top healthcare movers.
20 November 2025
···
Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk Stock Today (November 20, 2025): Wegovy Price Cuts, Alzheimer’s ‘Lottery Ticket’ Trials and Denmark GDP Put NVO Back in the Spotlight

Novo Nordisk’s U.S. ADR traded near $49 Thursday, steady after a 3% rebound, while Copenhagen shares rose about 2–2.5% to DKK 318–319. The company faces slowing GLP-1 demand, price cuts, and high-profile Alzheimer’s trials, with results expected December 3. Shares remain down over 10% in three months and nearly 46% year-to-date after guidance cuts.
20 November 2025
···
Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals (AGIO) Stock Slides on Mixed Phase 3 Sickle Cell Results From RISE UP Trial

Agios Pharmaceuticals’ Phase 3 RISE UP trial of mitapivat in sickle cell disease met its hemoglobin-response primary endpoint but failed to show a significant reduction in pain crises or fatigue. Shares fell sharply, dropping as much as 50% pre-market before paring losses. The company plans to meet with the FDA in early 2026 to discuss a potential U.S. marketing application.
19 November 2025
··
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

Kenvue shares traded near $16.13 midday, down 0.7%, after a U.S. appeals court signaled it may revive over 500 Tylenol-autism lawsuits. A Texas judge declined to block Kenvue’s $398 million dividend, which remains set for Nov. 26. The pending Kimberly-Clark deal implies $18.83 per share for KVUE, about 14% above its current price. Volume reached 21.1 million shares by 17:32 UTC.
18 November 2025
·····
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk Stock Today (Nov 18, 2025): $199 Wegovy/Ozempic Intro Offer Drives Focus; Controlling Shareholder Sells ConvaTec Stake; NVO Edges Lower

Novo Nordisk cut U.S. self-pay prices for Wegovy and Ozempic and launched a $199 two-month introductory offer for new patients. Shares fell 1.9% to $47.55 intraday as investors weighed pricing pressure and governance changes. Novo Holdings exited its 7.8% stake in ConvaTec in London. Trading volumes reached about 7.9 million shares by 16:12 UTC.
18 November 2025
··
Merck (MRK) Jumps as Oral PCSK9 Data Power Momentum; New Keytruda Diagnostic Cleared — What’s Moving the Stock Today (Nov. 12, 2025)

Merck (MRK) Stock Today, Nov 18, 2025: Shares Jump on Winrevair Phase 2 Win as Cidara Deal Builds Flu Portfolio

Merck shares rose about 3%–4% Tuesday after the company said its drug Winrevair met the main goal in a Phase 2 study for combined post- and precapillary pulmonary hypertension due to heart failure with preserved ejection fraction. Merck plans to advance the drug to Phase 3 trials. The update follows last week’s $9.2 billion deal to acquire Cidara Therapeutics.
18 November 2025
··
Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals (OLMA) Soars Over 200% After Roche Breast Cancer Trial Win — What It Means for Palazestrant and Investors on November 18, 2025

Olema Pharmaceuticals shares surged as much as 220% in pre-market trading on November 18 after Roche announced a Phase 3 win for its oral SERD giredestrant in early-stage breast cancer. The spike was driven by investor read-through to Olema’s similar drug palazestrant, not new Olema data. Volume hit 13.4 million shares, far above average. Shares later retreated toward the low-$20s during regular trading.
18 November 2025
·····
1 … 30 31 32 33 34 … 38

Stock Market Today

  • U.S. Natural Gas Prices Drop on Warmer Weather, Supply Factors Sustain Pressure
    March 20, 2026, 5:19 PM EDT. Natural gas prices for April Nymex delivery fell 2.24% as US weather forecasts turned warmer, potentially lowering heating demand. The Commodity Weather Group predicts above-average temperatures in the western US through March 29, pressuring prices. However, a recent Iranian attack on Qatar's Ras Laffan LNG export facility, which supplies 20% of global liquefied natural gas, could limit further declines. US dry gas production rose 4.8% year-on-year, nearing record highs with rigs increasing to a 2.5-year peak. Inventories surged by 35 billion cubic feet last week, well above average, indicating ample supply. Despite these bearish signals, rising electricity output and export potential from Qatar's damaged plant could support prices amid global supply disruptions.
Go toTop